In the last trading session, 2.62 million Neogenomics Inc (NASDAQ:NEO) shares changed hands as the company’s beta touched 1.27. With the company’s per share price at $13.78 changed hands at $1.15 or 9.11% during last session, the market valuation stood at $1.77B. NEO’s last price was a discount, traded about -38.68% off its 52-week high of $19.11. The share price had its 52-week low at $12.12, which suggests the last value was 12.05% up since then. When we look at Neogenomics Inc’s average trading volume, we note the 10-day average is 1.06 million shares, with the 3-month average coming to 779.05K.
Analysts gave the Neogenomics Inc (NEO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.67. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended NEO as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight.
Neogenomics Inc (NASDAQ:NEO) trade information
Instantly NEO was in green as seen at the end of in last trading. With action -22.10%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -16.38%, with the 5-day performance at -22.10% in the red. However, in the 30-day time frame, Neogenomics Inc (NASDAQ:NEO) is -24.16% down. Looking at the short shares, we see there were 3.86 million shares sold at short interest cover period of 5.35 days.
The consensus price target for the stock as assigned by Wall Street analysts is 18.5, meaning bulls need an upside of 25.51% from its current market value. According to analyst projections, NEO’s forecast low is 18 with 19 as the target high. To hit the forecast high, the stock’s price needs a -37.88% plunge from its current level, while the stock would need to soar -30.62% for it to hit the projected low.
Neogenomics Inc (NEO) estimates and forecasts
Data shows that the Neogenomics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -7.08% over the past 6 months, a 175.00% in annual growth rate that is considerably higher than the industry average of 16.70%.
The 2025 estimates are for Neogenomics Inc earnings to increase by 181.85%.
NEO Dividends
Neogenomics Inc is expected to release its next quarterly earnings report in February.
Neogenomics Inc (NASDAQ:NEO)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.21% of Neogenomics Inc shares while 99.49% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 100.70%. There are 99.49% institutions holding the Neogenomics Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 15.5612% of the shares, roughly 19.67 million NEO shares worth $272.82 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 11.1716% or 14.12 million shares worth $195.87 million as of 2024-06-30.
